Very few people have figured this out but a lot of gout suffers have. We have finally reached a time where there are tons of new ways of acute gout treatment. In fact gout treatment looks rosier now than ever before in the history of the disease. And that’s over 2,000 years.

A new age medicing has finally been approved for use in the EU countries, along with some other countries but as for right now the U.S has decided not to allow this as a treatment process.

TOPHI GOUT TREATMENT

Febuxostat also know Adenuric, is very encouraging as a new age treatment for gouty tophus . Tophi are the unsightly lumps of MSU crystals which develop in the bodies of gout sufferers after several years if there is no gout cure or sufficient alleviation to stop tophi growing.

Tophi will usual appear on the usual joint suspects first but can move to any joint in the body. It may even form inside you body on your organs although this rarely happens. They may be benign, they may not. If they aren’t, they can burst out of the skin, become ulcerated and septic - perhaps leading to that dangerous condition sepsis (septicemia) - destroy joints and grow into bone. Don’t worry not everyone who suffers from gout end up dealing with tophi, only about 255 will be affected by these lumps.

Tophi’s growth can be halted, and tophi dissolved if blood uric acid levels can be reduced to the
6 mg/dL, or below, mark. Studies have shown that this frequently happens at or below this level.
Short of surgical removal, which does sometimes become necessary to stop the problems noted above, lowering uric acid levels is the only way of dealing with tophi.

Febuxostat has been in phase 3 trials and has been very successful as a remedy for gout in the fight against tophi. This new age treatment is not a quick fix, as a matter of fact in the first 6 months of treatment it has very little effect but from 6 months to a year it works great. The trial was extened for another 2 years and they found a complete removal of tophi rose to 50% of all sufferers. Pegloticase, for which less data is currently available than for febuxostat, and which has not been approved anywhere yet, has also been more successful in trial extensions.